AlphaFold predicted structure
CDKN2B · P42772
Mean pLDDT
89.9/ 100
Confident
138 residues
Confidence breakdown
- Very high(≥ 90)81%
- Confident(70–90)8%
- Low(50–70)2%
- Very low(< 50)9%
Open interactive 3D viewer
AlphaFold (Jumper et al., 2021) · CC BY 4.0
CDKN2B
Chr 9p21.3cyclin dependent kinase inhibitor 2B
- Aliases:
- P15, MTS2, INK4B, TP15, CDK4I
- MANE:
- ENST00000276925.7
Annotations refreshed 9 hours ago.
Predicted protein structure
Clinical relevance (Genomics England PanelApp)
Moderate Evidence (Amber)
Familial hyperparathyroidism or hypocalciuric hypercalcaemia
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownInherited renal cancer
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Disease associations (Open Targets)
neurodegenerative disease
0.57Alzheimer disease
0.55open-angle glaucoma
0.54type 2 diabetes mellitus
0.51glaucoma
0.51coronary artery disorder
0.51glioma
0.51breast cancer
0.51Parkinson disease
0.50basal cell carcinoma
0.50
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Protein function (UniProt)
Cyclin-dependent kinase 4 inhibitor B
Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest
Diseases associated with CDKN2B
Curated MONDO disease pages that list CDKN2B among their top associated genes.